



Half Year Presentation

June 2025





Managing Director

Andrew O'Keefe

We are pleased to report a strong performance for the first six months ended June 2025. Our organisation's fundamentals remain solid, reflecting the strength of our strategy and product offerings.

The Board and management are committed to sustaining growth whilst making strategic investments in our brands and markets.

For personal use only

About Vita Life Sciences




For personal use only

Financial Highlights

- Record first half Revenue
- Gross profit margin ↑ 2% to 60%
- Cash conversion: strong 109%
- Strong balance sheet with no borrowings
- Share buyback: \$1.2M

DIVIDEND

A fully franked interim dividend of 4.5 cents per share was declared for the period, representing an increase of 1.0 cent per share on PCP.



The Group maintains a strong balance sheet with equity of \$52.6 million and cash reserves of \$29.4 million, with no bank borrowings.

Half Year Results

Half year ended June	2025 \$'m	2024 \$'m
Revenue	45.5	39.5
EBITDA	7.0	5.9
EBIT	6.5	5.6
Profit before tax	6.8	6.0
Profit after tax	4.8	4.3
EPS (Basic – cents/ share)	8.61	7.84
Dividend (cents / share)	4.5	3. 5



Balance Sheet

Balance Sheet as at	Jun 2025 \$'m	Dec 2024 \$'m
Current assets	59.2	58.9
Non-current assets	15.4	13.0
Total assets	74.6	71.9
Current liabilities	20.1	19.3
Non-current liabilities	1.9	0.3
Total Liabilities	22.0	19.6
Net Assets	52.6	52.3

Cash Flow

Cash Flow for the half year ended June	2025 \$'m	2024 \$'m
Receipts from customers	47.0	40.4
Payments to suppliers and employees	(39.5)	(36.6)
Gross operating cash flow	7.5	3.8
EBITDA	6.9	5.9
Gross operating cash flow / EBITDA	109%	65%
Net interest	0.2	0.5
Income tax paid	(1.1)	(1.6)
Operating cash flows	6.6	2.7
Cash flows for investing	(0.7)	-
Net movements in financing	(5.1)	0.4
Cash flows from financing	0.8	3.1
Net foreign exchange differences	-	-
Net increase in cash reserves	0.8	3.1
Cash at beginning of period	28.6	24.6
Cash at end of period	29.4	27.7



Operational Highlights

Segment performance - Broad based growth across core markets, supported by strong performances across all major channels and positive consumer sentiment.

- Australia **up 8%**
- Malaysia & Singapore **up 54%**

Market initiatives

- Continued distribution expansion in Australia, Malaysia and Singapore, with targeted initiatives to strengthen market penetration.
- Revised market strategy in China deployed.
- Appointment of new exclusive distributor for Herbs of Gold across the Pharmacy and e-commerce channels.

Marketing and Brand Investment

- Advertising and promotional investment increased by 26% on PCP, driving brand visibility and consumer engagement.



Our people

We have over 300 employees in the Vita Life Sciences Group across Australia, Malaysia, Singapore, China, Indonesia and Vietnam. We have teams of qualified naturopaths, nutritionists, herbalists, biotechnologists, and pharmacists. and online retailers in the health food and pharmacy sector.

OVER
300
EMPLOYEES

Our markets

We continue to evolve and expand our global presence.
We are currently in 6 markets.

AUSTRALIA
MALAYSIA
SINGAPORE
VIETNAM
INDONESIA
CHINA

Our partners

Our products are available across some of the biggest offline and online retailers in the health food and pharmacy sector.



Marketing

Our marketing investment combines global scale with a deep understanding of local audiences. We connect with millions of consumers through coordinated activity across television, digital, social, radio, outdoor, print, and in-store channels. By integrating these platforms, we ensure our campaigns are relevant, consistent, and accessible, strengthening engagement and building lasting connections with diverse communities.


For personal use only

ACTIVATE ENERGY

Complex contains activated
support energy production.
the label and follow the directions for use.



herbs of gold™





2025 NPD H1

For personal use only



There are currently over **350 products** registered across the business.

11 new products launched across Australia, Malaysia and Singapore.


Social impact & corporate responsibility



At Vita Life Sciences, we are dedicated to enhancing our Environmental, Social and Governance (ESG) strategy by embedding initiatives into our business operations to uphold the high standards we set for ourselves and our partners. We have developed partnerships with charities, launched team initiatives and are building programs to enhance education and literacy to further improve on this. These efforts reflect our commitment to making a positive impact on our communities. Our goal is to drive sustainable growth and create long-term strategies that benefit both our business and the planet.



Strategic priorities



Outlook

The Board is encouraged by the Group's first half performance, particularly the strength in Australia, Malaysia and Singapore and expects the momentum to be maintained going into the second half.

The Group remains committed to delivering full year revenue and profit before tax growth over PCP. Full year guidance to be provided in QTR4.



ANDREW O'KEEFE
MANAGING DIRECTOR



CHIN L KHOO
CHIEF FINANCIAL OFFICER



+61 2 9545 2633



Suite 802, Level 8, 1-5 Chalmers Crescent
Mascot NSW 2020 Australia



enquiries@vitalifesciences.com.au



vitalifesciences.com

Disclaimer

This document has been prepared by Vita Life Sciences Limited (**Vita Life Sciences or VLS**) and comprises written material/slides for a presentation concerning Vita Life Sciences.

The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Vita Life Sciences that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct, Except for any statutory liability which cannot be excluded, Vita Life Sciences and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Vita Life Sciences disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Vita Life Sciences since the date of this presentation.

